Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
161.52
+7.09 (4.59%)
May 13, 2025, 4:00 PM - Market closed
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
$391,848
Profits / Employee
-$363,125
Market Cap
9.75B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,017 | 138 | 15.70% |
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ASND News
- 15 hours ago - New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide) - GlobeNewsWire
- 1 day ago - New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism - GlobeNewsWire
- 8 days ago - Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 - GlobeNewsWire
- 12 days ago - Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Ascendis Pharma Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 19 days ago - Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 - GlobeNewsWire
- 4 weeks ago - Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory - Seeking Alpha
- 6 weeks ago - Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia - GlobeNewsWire